biostudies-literatureHellstrom ANEI NIH HHSNICHD NIH HHSDepartment of Health576-86https://www.ebi.ac.uk/biostudies/studies/S-EPMC5069563biostudies-literatureUnknown105(6)<h4>Unlabelled</h4>Poor postnatal growth after preterm birth does not match the normal rapid growth in utero and is associated with preterm morbidities. Insulin-like growth factor 1 (IGF-1) axis is the major hormonal mediator of growth in utero, and levels of IGF-1 are often very low after preterm birth. We reviewed the role of IGF-1 in foetal development and the corresponding preterm perinatal period to highlight the potential clinical importance of IGF-1 deficiency in preterm morbidities.<h4>Conclusion</h4>There is a rationale for clinical trials to evaluate the potential benefits of IGF-1 replacement in very preterm infants.Acta paediatrica (Oslo, Norway : 1992)Insulin-like growth factor 1 has multisystem effects on foetal and preterm infant development.PMC5069563NF-SI-0513-10012R01 EY017017NF-SI-0508-10274U54 HD090255Beardsall KHellstrom ADunger Dvan Marter LHallberg Bvan Weissenbruch MLey DHansen-Pupp IHard ALRamenghi LALofqvist CSmith LEfalseInsulin-like growth factor 1 has multisystem effects on foetal and preterm infant development.<h4>Unlabelled</h4>Poor postnatal growth after preterm birth does not match the normal rapid growth in utero and is associated with preterm morbidities. Insulin-like growth factor 1 (IGF-1) axis is the major hormonal mediator of growth in utero, and levels of IGF-1 are often very low after preterm birth. We reviewed the role of IGF-1 in foetal development and the corresponding preterm perinatal period to highlight the potential clinical importance of IGF-1 deficiency in preterm morbidities.<h4>Conclusion</h4>There is a rationale for clinical trials to evaluate the potential benefits of IGF-1 replacement in very preterm infants.2016-01-01T00:00:00Z2016 Jun2021-02-21T12:05:00Z2019-03-27T02:27:03ZS-EPMC50695632683374310.1111/apa.13350